%0 Journal Article
%A Ruiz-Sánchez, Daniel
%A Alaguero Calero, Miguel
%A Sastre-Heres, Alejandro José
%A Iglesias García, María Teresa
%A Calleja Hernandez, Miguel Angel
%A Martínez Martinez, Fernando
%A Peña-Díaz, Jaime
%T Effectiveness of the bevacizumab-irinotecan regimen in the treatment of recurrent glioblastoma multiforme: Comparison with other second-line treatments without this regimen.
%D 2012
%U http://hdl.handle.net/10668/1406
%X A retrospective cohort study was conducted to analyse the effectiveness of bevacizumab and irinotecan (BVZ/CPT-11) as a second-line treatment in patients with primary glioblastoma multiforme (GBM) in comparison with a control group that were not administered BVZ/CPT-11 at the first recurrence. The difference in overall survival (OS) between the two groups was used as a predictor of effectiveness. OS was calculated according to prognostic factors and gender. A total of 28 and 32 patients were enrolled in the BVZ/CPT-11 cohort and control group, respectively. The median OS was 17.94 months (95% CI, 14.91-20.96) in the BVZ/CPT-11 treatment cohort and 10.97 months (95% CI, 7.65-14.30) in the control cohort. The results obtained on the effectiveness of BVZ/CPT-11 treatment in patients with primary GBM are consistent with data from previous studies. No significant differences were identified in OS based on prognostic factors; therefore, the latter cannot be used to select patients who would incur the greatest benefits from BVZ/CPT-11 treatment.
%K Bevacizumab
%K Irinotecan
%K Effectiveness
%K Antineoplásicos
%K Camptotecina
%K Análisis de Supervivencia
%K Estudios de Cohortes
%K Anticuerpos Monoclonales
%K Resultado del Tratamiento
%~